Skip to main content

Market Overview

Why This Analyst Is Cautious On Biogen

  • Biogen Inc (NASDAQ: BIIB) are down 12 percent since January 4, and trading close to their 52-week low.
  • Credit Suisse’s Alethia Young initiated coverage of the company with a Neutral rating and a price target of $322.
  • More clarity is required on the company’s pipeline and base business growth rate before considering an investment in the stock, Young stated.

Analyst Alethia Young mentioned that Biogen’s shares were fairly volatile in 2015, largely driven by the pipeline results for LINGO and Alzheimer’s, slowing Tecfidera sales, concerns over generics and pricing in multiple sclerosis, and competition in the hemophilia franchise.

“Slowing base business combined with risky but potentially game-changing pipeline has led to multiple contraction of Biogen shares,” Young noted.

The analyst pointed out that Biogen’s base businesses continue to have headwinds and that the long-term business growth could be hit by competition from new regimes.
Potential catalysts that could boost Biogen’s future performance include:

  1. Synergy MS study and anti-LINGO1 data in mid-2016
  2. BAN2401 top-line data in AD
  3. E2609 BACE safety look
  4. Solanezumab Phase 3 data in October 2016
  5. Adacanumab titration updates on the PRIME AD study.

Young said that Biogen’s long-term growth is risky, since it is “heavily weighted towards pipeline that we deem risky.” The company’s near-term pipeline opportunities include Ocrelizumab for MS and nusinersen for spinal muscular atrophy.

Latest Ratings for BIIB

Feb 2021Cantor FitzgeraldMaintainsNeutral
Feb 2021Credit SuisseMaintainsOutperform
Feb 2021Morgan StanleyMaintainsOverweight

View More Analyst Ratings for BIIB
View the Latest Analyst Ratings


Related Articles (BIIB)

View Comments and Join the Discussion!

Posted-In: Alethia Young Credit SuisseAnalyst Color Initiation Analyst Ratings

Latest Ratings

PBTruist SecuritiesMaintains88.0
CFRTruist SecuritiesMaintains111.0
FANGTruist SecuritiesMaintains105.0
SBNYCredit SuisseMaintains250.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at